Roberts, H. L., Donohoe, W. T. A., Hewitt, Sheila, and Price Evans, D. A. (1977) . Thorax, 32, [84] [85] [86] [87] . Total T lymphocytes in primary bronchial carcinoma. Percentage and absolute levels of circulating T lymphocytes were measured in 48 patients with bronchial carcinoma. These were compared with control values from nine healthy adults and 19 age-matched patients with benign disorders. A further 20 patients who had been given postoperative immunotherapy after complete resection of bronchial carcinoma were also studied. There was no significant difference in the mean percentage T cells between the groups. Lymphopenia, however, was a feature of the bronchial cancer patients with metastatic disease. This resulted in a significant diminution of absolute T cells in this group. There is no evidence, with the technique employed in this study, of a total T-cell deficiency in early bronchial carcinoma.
There is increasing interest in the immunological aspects of neoplasia in both reticuloendothelial and solid tumours. Inefficiency of the immune surveillance mechanism, allowing the proliferation of clones of abnormal cells, has been suggested as an aetiological factor in the development of cancer (Bumet, 1970) . Neoplasia, especially in its more advanced stages, is associated with a diminution of the cell-mediated immune response. The fundamental question, however, whether the immunological deficiency precedes the development of the tumour or is secondary to the presence of the tumour, remains unanswered.
At least two functionally distinct populations of small lymphocytes have been recognised (Greaves et al., 1974) . T lymphocytes are concerned with the cell-mediated immune function while B lymphocytes are involved in humoral antibody production. Numerous studies have been reported on lymphocyte subpopulations in patients with various solid tumours (Catalona et al., 1974; Wanebo et al., 1975; Whitehead et al., 1976) , including bronchial carcinoma (Anthony et al., 1975; Dellon et al., 1975; Gross et al., 1975 (2)) remains unknown to the experimenters. The mean age of the patients with benign disease was similar to the mean age of the cancer patients.
In view of the known factors depressing in vitro assays of cellular immunity, patients were excluded if they had received chemotherapy, steroids or radiotherapy (Catalona et al., 1974) (Thorsby and Bratlie, 1970) . This was then centrifuged at 400 g for 40 minutes at 40C. Interface cells, however, were often found to contain a significant proportion of neutrophils, erythrocytes, and platelets, rendering accurate rosette counting difficult and timeconsuming.
The preparation was, therefore, modified by the use of carbonyl iron (Doughty and Gelsthorpe, 1971) (Figure) . The seven patients with metastatic disease, whose histological diagnosis was not known, had similar values to the other 18 in whom the histology was known.
In view of the small numbers, analysis of each histological type was not performed. As might be expected, there were far fewer cases of oat-cell tumour in the 'localised' disease category (1 out of 23) than in the metastatic group (7 out of 18) (see Table 2 ).
Discussion
Differing patterns of immunological deficiency are found in patients with cancer. The clearest (Aisenberg, 1976) . In the more common cancers, the situation is not so clearcut. Head and neck cancers demonstrate immunological deficiencies early in the course of the disease (Wanebo et al., 1975) and these get worse as the disease progresses. In women with breast cancer, generalised immune deficiency becomes pronounced only with advanced disease, but T lymphocyte levels are diminished in the early stages (Whitehead et al., 1976) . In lung cancer, studies have shown cell-mediated immune deficiency at various stages of the disease (Krant et al., 1968; Brugarolas et al., 1973; Dellon et al., 1975) . The finding in the present research of absence of depression of T cells in both proportional and absolute terms in localised primary lung cancer is not in accord with most other studies (Anthony et al., 1975; Dellon et al., 1975; Gross et al., 1975) . Dellon et al. (1975) , in a large series of patients (using a similar rosette-forming technique to that employed in the present study but without a carbonyl iron step), showed that T-cell levels in preoperative squamous, oat-cell, and undifferentiated carcinoma correlated well with the extent of the tumour. Even localised disease showed a significant diminution in absolute T-cell levels compared to normals.
Our findings of normal T lymphocyte levels in early disease and of lymphopenia with advanced carcinoma are, however, similar to functional lymphocyte studies performed by Barnes et al. (1975) . These authors found that phytohaemagglutinin (PHA) responsiveness of peripheral lymphocytes of newly presenting patients with lung cancer showed no difference from healthy ageand sex-matched normal controls. There was, however, a significant diminution in PHA response in the preterminal phase of the disease. Harris et al. (1975) , in a study of a variety of disseminated solid tumours (but excluding lung cancer), found the T-cell count of such patients no different from that of healthy control subjects. Their technique differed in detail from that employed in the present study, for example, by the preliminary exposure of the lymphocytes to fetal calf serum. Similar results of both T-cell numbers and function in bronchial carcinoma have been found by Amlott and Knight (personal communication).
The literature on T-cell estimation is unfortunately plagued by a variety of differing techniques. Our present study adds yet another method but we feel justified in its use in eliminating neutrophils and thereby increasing the efficiency and accuracy of the counting procedure.
The technique described with its long incubation period measures the total T-cell count in peripheral blood. It may well be that only a proportion of the T cells are concerned with tumour immune recognition, and alternative techniques are necessary to define such a subpopulation. Fudenberg et a!. (1975) , using the 'active' rosette test, ie, allowing the SRBC and lymphocytes to incubate for a short time, claim that significant differences occur between healthy controls and early cancer patients.
Our 
